Log In Get Started
Press Releases May 19, 2026 08:00 AM

BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

BioCardia to engage in virtual fireside chat at Alliance Global Partners Healthcare Showcase

By Marcus Reed BCDA

BioCardia, Inc., a Nasdaq-listed company specializing in cellular therapeutics for cardiovascular and pulmonary diseases, announced its upcoming participation in a virtual fireside chat during the Alliance Global Partners Healthcare Company Showcase. The event, scheduled for May 20, 2026, will provide insights into BioCardia's therapeutic platforms and advancements.

BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
BCDA

Key Points

  • BioCardia is focused on cellular and cell-derived therapies for heart and lung diseases.
  • The company utilizes proprietary platforms including CardiAMP® and CardiALLO™ for treatment development.
  • Participation in the A.G.P. Healthcare Showcase offers exposure to investors and stakeholders in the healthcare sector.

SUNNYVALE, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, will participate virtually in a fireside chat at A.G.P.'s Healthcare Company Showcase.

Fireside Chat Details:

  • Time: 11:40 AM ET
  • Date: Wednesday, May 20, 2026

Investors can register for the conference and view the fireside chat here.

About BioCardia®

BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit: www.BioCardia.com.


Risks

  • The fireside chat itself does not present new product or financial disclosures, limiting immediate impact.
  • Market interest in biotech companies can be sensitive to clinical trial results, regulatory developments, and commercialization prospects not addressed here.
  • Broader healthcare market volatility and competition in cell therapy sectors may affect BioCardia's outlook.

More from Press Releases

Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026 SOLV Energy Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares of Class A Common Stock Jun 4, 2026 NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option Jun 4, 2026 DLH Announces Filing of New Shelf Registration Statement Jun 4, 2026 FutureCorp Space Acquisition 1 Announces Pricing of $200,000,000 Initial Public Offering Jun 4, 2026